New triple therapy before lung cancer surgery shows promise in major trial
NCT ID NCT06437977
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This phase 3 trial tests whether adding targeted radiation (SBRT) to immunotherapy (toripalimab) and chemotherapy before surgery helps people with stage II-III non-small cell lung cancer live longer without the cancer coming back. About 478 participants will be randomly assigned to receive either the triple combination or just immunotherapy plus chemo before their operation. The study measures how long patients stay cancer-free and how many have no cancer cells left in their removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II-III NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.